ReviewChinese journal of cancer research = Chung-kuo yen cheng yen chiu2014
Function of PCA3 in prostate tissue and clinical research progress on developing a PCA3 score.
Review in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Affordable ultrasensitive electrochemical detection of PCA3 for early prostate cancer diagnosis.Scientific reports · 2025Article
- Time-Resolved Förster Resonance Energy Transfer Nanoassay Based on CdTe Quantum Dots for Sensitive Detection of Prostate Cancer Antigen 3.ACS applied nano materials · 2025Article
- Natural products and long non-coding RNAs in prostate cancer: insights into etiology and treatment resistance.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Exploring the role of noncoding RNAs in cancer diagnosis, prognosis, and precision medicine.Non-coding RNA research · 2024Review
- Deregulated Long Non-Coding RNAs (lncRNA) as Promising Biomarkers in Hidradenitis Suppurativa.Journal of clinical medicine · 2024Article
- Prostate cancer knowledge and barriers to screening among men at risk in northern Tanzania: A community-based study.Cancer treatment and research communications · 2024Article
- Article
- PCA3 in Prostate Cancer.Methods in molecular biology (Clifton, N.J.) · 2021Article
- A review of studies examining the association between genetic biomarkers (short tandem repeats and single-nucleotide polymorphisms) and risk of prostate cancer: the need for valid predictive biomarkers.Prostate international · 2020Review
- UrinaryEXCLI journal · 2020Article
- Long Non-coding RNA Expression in Anaplastic Thyroid Carcinomas.Endocrine pathology · 2019Article
- Exosomes as carriers transporting long non‑coding RNAs: Molecular characteristics and their function in cancer (Review).Molecular medicine reports · 2019Review
- Gene regulation of mammalian long non-coding RNA.Molecular genetics and genomics : MGG · 2018Review
- Biomarkers of genome instability and cancer epigenetics.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- LncRNAs and cancer.Oncology letters · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer gene 3 (PCA3, also known as DD3) is a new biomarker that could improve the accuracy of prostate cancer diagnosis. It is a great biomarker with fairly high specificity and sensitivity. The incidence of prostate cancer is rising steadily in most countries. The commonly used prostate-specific antigen (PSA) test once gave people hope for early diagnosis of prostate cancer. However, the low specificity of the PSA test has resulted in a large number of unnecessary biopsies and overtreatment. During the past decade, many new prostate cancer biomarkers have been found. Among these, PCA3 is the most promising. Due to its great performance in distinguishing prostate cancer from other prostate conditions, PCA3 could likely be applied for early diagnosis of prostate cancer, patient follow-up, prognosis prediction, and targeted therapy. After years of research, we have obtained some knowledge about the sequence of PCA3 gene. We have also determined the relationship between PCA3 and the proliferation of prostate cancer cells and learned some information about how PCA3 affects tumor-related genes and proteins. A PCA3 score has been created, and it has been used in a variety of studies. Some researchers have even applied PCA3 to targeted therapy and obtained a good effect in vitro. This review describes the current state of research, and explores the future prospects for PCA3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.